样式: 排序: IF: - GO 导出 标记为已读
-
Parasomnia induced by lemborexant: a case report. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-03-11 Toshinori Nakamura, Yusuke Arai, Tetsuya Hagiwara, Ryosuke Kitoh, Daimei Sasayama, Shinsuke Washizuka
Lemborexant, an orexin receptor antagonist, is effective not only for sleep disorders but also for preventing and treating delirium. To date, no complex sleep-related behaviors due to lemborexant have been reported. Herein, we present the case of a 69-year-old male patient who was hospitalized for oral floor and tongue cancer and developed delirium after surgery; however, upon lemborexant dosage increase
-
Recent updates on treatment patterns in patients with treated attention-deficit/hyperactivity disorders from a nationwide real-world database in South Korea. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-03-11 Yoon Cho, Ah-Young Kim, Sukhyang Lee, Hankil Lee
The prevalence of attention-deficit/hyperactivity disorder (ADHD) is steadily increasing across Korea. We analyzed ADHD patients with ADHD medications (Rx) characteristics and treatment patterns compared to patients without Rx and identified the differences between pediatric-/adult- and active-/transient-patients with Rx. Using a nationwide claims dataset from 2020 to 2021, we conducted a prevalence-based
-
Prospective, comparative, pilot study of maintenance treatment in comorbid bipolar disorders with post-traumatic stress disorder. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-02-22 Hernán F Guillen-Burgos, Juan F Gálvez-Flórez, Sergio Moreno-Lopez, Angela T H Kwan, Roger S McIntyre
There is limited real-world evidence that evaluates the impact of monotherapy vs. combination therapy as a maintenance treatment in comorbid post-traumatic stress disorder (PTSD) in bipolar disorder (BD). Our aim was to compare lithium vs. lithium plus quetiapine in maintenance treatment in a sample of comorbid BD with PTSD. An exploratory, comparative pilot study over a 28-week period in 34 comorbid
-
Micronized/ultramicronized palmitoylethanolamide improves depression and fatigue in coronavirus disease 2019 (COVID-19) survivors. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-02-22 Aurora Merolla, Rebecca De Lorenzo, Giacomo Paolazzi, Sara Critelli, Mariagrazia Palladini, Sarah Damanti, Giordano Vitali, Valentina Canti, Marta Cilla, Sabina Martinenghi, Elisabetta Falbo, Marica Ferrante, Jacopo Castellani, Giacomo Pacioni, Cristiano Magnaghi, Anna Fumagalli, Mario G Mazza, Francesco Benedetti, Patrizia Rovere-Querini
Coronavirus disease 2019 (COVID-19) may lead to neuropsychiatric sequelae. Palmitoylethanolamide (PEA) is an anti-inflammatory and neuroprotective amide used in depressive syndromes. Here we investigate whether micronized/ultramicronized (m/um) PEA improves neuropsychiatric sequelae in COVID-19 survivors. Patients evaluated at our post-COVID-19 outpatient clinic between February and August 2021 and
-
Evaluating the influence of nonproblematic alcohol intake on the outcome of major depression. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-02-22 Víctor Navarro, Joana Guarch, Ilham Boulahfa, Laia Tardón, Amadeu Obach, Cristóbal Gastó, Manel Vila-Vidal
The effect of light or moderate alcohol intake on the outcome of patients with major depression taking antidepressants is a question that remains unanswered. The main objective of this study was to assess the association between light or moderate alcohol consumption and the acute response (efficacy and tolerability) to pharmacological treatment in unipolar major depression. Efficacy and tolerability
-
Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-02-13 Karim Abdel Aziz, Hind Mohd Ahmed, Emmanuel Stip, Dina Aly El-Gabry
The risk of metabolic syndrome (MetS) has been attributed to antipsychotic use in psychiatric patients. To date, there is limited data on the relationship between antipsychotic polypharmacy and MetS in patients with schizophrenia, schizoaffective disorder and bipolar disorder. Therefore, we aimed to investigate the rate of MetS in patients with these disorders receiving antipsychotic monotherapy and
-
UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-02-02 Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren
This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). Patients prescribed Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in patient-reported outcome
-
Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-01-25 Michael E Thase, Paul P Yeung, Ludmyla Rekeda, Meng Liu, Shane Varughese
To characterize the safety and tolerability of adjunctive cariprazine in patients with major depressive disorder (MDD) and inadequate response to monotherapy antidepressant treatment (ADT). Post hoc analyses evaluated pooled data from 2 fixed-dose phase 3 cariprazine studies (1.5 and 3 mg/d [approved doses for MDD]). In a separate safety analysis, cariprazine 0.1-4.5 mg/d was evaluated using data from
-
Differed spontaneous dissociative symptoms following the use of esketamine intranasal spray in a patient suffering from treatment-resistant depression: a case report. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-01-22 Louis Chevalier, Samuel Bulteau, Louis Cheval, Jalal Charron, Anne Sauvaget, Andrew Laurin
Intranasal esketamine is used in France for treatment-resistant depression. Dissociative symptoms are common side effects during treatment sessions. We report a case of delayed spontaneous dissociative symptoms following esketamine administration. A 20-year-old female with treatment-resistant depression received esketamine treatment. Dissociative symptoms occurred during sessions and persisted at a
-
Is Pilates effective in improving depressive disorders? A comprehensive overview. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-01-22 Francesca Legnani, Lorenzo Tassi, Teresa Surace, Enrico Capuzzi, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli
Depressive disorders are disabling conditions that account for high social costs. Pilates demonstrated to have several beneficial effects on health. Objective of this manuscript was to systematically review the literature about the effects of Pilates on depressive disorders. A bibliographic search was conducted in the main database sources (Pubmed, Medline, and Scopus). The inclusion criteria consisted
-
Case report and systematic review of cerebellar vermis alterations in psychosis. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-01-22 Nicola Dusi, Cecilia Maria Esposito, Giuseppe Delvecchio, Cecilia Prunas, Paolo Brambilla
Cerebellar alterations, including both volumetric changes in the cerebellar vermis and dysfunctions of the corticocerebellar connections, have been documented in psychotic disorders. Starting from the clinical observation of a bipolar patient with cerebellar hypoplasia, the purpose of this review is to summarize the data in the literature about the association between hypoplasia of the cerebellar vermis
-
Change in absolute neutrophil count after COVID-19 infection in patients using clozapine versus other antipsychotics. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-01-22 Seong Hoon Jeong, Mi Gyung Lee, Yong Sik Kim, In Won Chung
It was reported that patients who contracted COVID-19 while taking clozapine exhibited a distinct hematological response. However, the absence of control groups made it difficult to attribute it to clozapine. The changes in absolute neutrophil counts (ANCs) during the 4 weeks after COVID-19 infection were compared between the two groups of patients with severe mental illnesses (SMIs) (49 patients using
-
Immunomodulatory options for neurodevelopmental spectrum conditions: are we there yet? Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2024-01-22 Martina Arenella
About 3-7% of the worldwide population is diagnosed with a neurodevelopmental condition, including autism and attention-deficit hyperactivity disorder. Nonetheless, the aetiology of these conditions is unclear and support options are limited or not effective for all those diagnosed. Cumulating evidence, however, supports a role of the immune system in neurodevelopment, and immune dysregulations have
-
The role of benzodiazepines in common conditions: a narrative review focusing on lormetazepam. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-12-27 Stefano Pallanti
This review aimed to examine the place of benzodiazepines, specifically lormetazepam, in the treatment of insomnia, including during pregnancy or in patients with psychodermatoses. PubMed was searched for the term "lormetazepam" in association with MeSH terms encompassing anxiety, insomnia/sleep disorders, pregnancy/gestation, and psychodermatoses/skin disorders. English-language articles up to 31
-
A comprehensive overview of post-stroke depression treatment options. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-12-27 Alberto Raggi, Alessandro Serretti, Raffaele Ferri
Nearly one-third of all stroke patients develop depression at any time after a stroke, and its presence is associated with unfavorable outcomes. This narrative review aims to provide a synopsis of possible pharmacological and non-pharmacological treatment modalities for post-stroke depression (PSD). Several studies have demonstrated the efficacy and safety of selective serotonin reuptake inhibitors
-
Comparative efficacy of various pharmacologic treatments for alcohol withdrawal syndrome: a systematic review and network meta-analysis. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-12-27 Li Qu, Xue-Ping Ma, Alimujiang Simayi, Xiao-Li Wang, Gui-Ping Xu
This study was to compare multiple classes of medications and medication combinations to find alternatives or additives for patients not applicable to benzodiazepines (BZDs). We performed a network meta-analysis to assess the comparative effect of 11 pharmacologic treatments in patients with alcohol withdrawal syndrome. Forty-one studies were included, comprising a total sample size of 4187 participants
-
Rhabdomyolysis during adjunctive treatment with cariprazine in a clozapine-resistant schizophrenia patient. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-12-27 Kilian Lommer, Franziska Tutzer, Alex Hofer
We report the case of a 49-year-old male treatment-resistant schizophrenia patient, whose treatment with clozapine and sertraline was supplemented with cariprazine 1.5 mg/day while regularly presenting for electroconvulsive therapy. After 3 weeks of adjunctive treatment with cariprazine, blood tests revealed pronounced signs of rhabdomyolysis, including a creatine kinase serum level of 20 386 U/L and
-
Spanish versions and validation of a series of rating scales and visual analogue scales to assess the subjective effects of cannabis. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-11-20 Alberto Sainz-Cort, Marta Martín-Islas, Genís Oña, Daniel Jimenez-Garrido, Miriam López-Navarro, Elena Muñoz-Marron, Raquel Viejo-Sobera, Jose Carlos Bouso
Cannabis is being legalized for medical and recreational purposes all around the world. However, the understanding of the psychological effects of cannabis is still limited, and it has been previously linked to mental disorders such as schizophrenia. Lately, new scales have been created and adapted to measure its psychological effects. The aim of this study is to create Spanish versions of some of
-
Impact of long-acting injectable aripiprazole on the concomitant medication and antipsychotic polypharmacy: a retrospective, observational study of 127 patients with psychosis. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-11-20 Junhee Lee, Sanghoon Oh, Sun-Young Moon, Silvia Kyungjin Loh, Minah Kim, Tae Young Lee, Jun Soo Kwon
Antipsychotic polypharmacy (APP) has become prevalent over the years, but several concerns have been raised over APP. Accumulating evidence suggests that aripiprazole long-acting injectable (LAI) may reduce the rate of APP, but the association remains speculative. This retrospective observational study included 127 patients with psychosis and observed them for 1.8 ± 1.3 years, up to 4 years. Prescription
-
The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-11-20 Dilara Çirakman, Ersin Hatice Karslioğlu, Neşe Burcu Bal, Ali Çayköylü
The effective treatment in the early stages of schizophrenia is of critical importance to improve the prognosis. Schizophrenia affects patients' relatives too. The effects of early or late initiation of long-acting injectable antipsychotics (LAI-APs) on the patient have been shown, yet their effects on the caregiver are still unknown. We aimed to determine how the time of initiation of LAI-APs affects
-
Diabetes mellitus in patients with chronic bipolar disorder: prevalence, clinical correlates and relationship with homocysteine. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-11-20 Li Mu, Dachun Chen, Meihong Xiu, Huixia Zhou, Dongmei Wang, Xiang-Yang Zhang
Comorbid diabetes mellitus in patients with bipolar disorder may contribute to increased morbidity and mortality. To determine the prevalence of diabetes mellitus in bipolar disorder patients and its clinico-demographic and homocysteine correlates, we conducted a cross-sectional survey of 195 bipolar disorder inpatients. They received questionnaires, clinical measurements and laboratory tests to assess
-
Relevance of pharmacogenetic analyses and therapeutic drug monitoring of antidepressants for an individualized treatment of peripartum psychopathology. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-11-20 Anna Colombo, Rita Cafaro, Ilaria Di Bernardo, Marta Mereghetti, Lucia Cerolini, Luca Giacovelli, Federica Giorgetti, Simone Vanzetto, Nicolaja Girone, Valeria Savasi, Irene Cetin, Emilio Clementi, Monica Francesca Bosi, Caterina Adele Viganò, Bernardo Dell'Osso
Psychiatric disorders burden the peripartum period, often requiring psychopharmacological treatment, including antidepressants. Efficacy and tolerability of antidepressants are influenced by the physiological changes of the peripartum and individual metabolic profiles, which in turn can be modified by pregnancy. The objective of this study is to assess the relationship between antidepressants' pharmacokinetic
-
Antidepressants use in Italy: an ecological study of national and regional trends and associated factors. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-11-15 Simone Amendola, Michael Pascal Hengartner
The present study aimed to (1) provide an update on trends in AD consumption both at the national and regional unit of analysis for the period 2000-2020 in Italy and (2) analyze sociodemographic and healthcare system-related factors associated with AD prescribing at the regional-population level between 2000 and 2019. Data were extracted from reports of the Italian Medicines Agency and databases of
-
The impact of mild behavioral impairment on the prognosis of geriatric depression: preliminary results. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-11-15 Camilla Elefante, Giulio Emilio Brancati, Gabriele Pistolesi, Salvatore Amadori, Samuele Torrigiani, Filippo Baldacci, Roberto Ceravolo, Zahinoor Ismail, Lorenzo Lattanzi, Giulio Perugi
Our study aimed to examine how the presence of Mild Behavioral Impairment (MBI) symptoms influenced the outcome of late-life depression (LLD). Twenty-nine elderly (≥ 60 years) depressive patients, including eleven (37.9%) with MBI, were recruited and followed-up on average for 33.41 ± 8.24 weeks. Psychiatric symptoms severity and global functioning were assessed, respectively, using the Brief Psychiatric
-
Efficacy and safety of clozapine in treatment-resistant psychotic patients with DiGeorge syndrome (22q11.2 deletion syndrome): a case series. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-10-13 Isabella Berardelli, Mariarosaria Cifrodelli, Carlotta Giuliani, Giulia Antonelli, Carolina Putotto, Federica Pulvirenti, Maurizio Pompili
Neuropsychiatric disorders are common manifestations in 22q11.2 deletion syndrome (22q11.2DS-DiGeorge Syndrome). Although many patients with 22q11.2DS receive antipsychotic treatment for psychotic disorders, little is known about the safety and tolerability of antipsychotics in 22q11.2DS and resistant psychosis. The aim of this case series is to describe the effectiveness as well as safety and tolerability
-
Type 2 diabetes mellitus is associated with manic morbidity in elderly patients with mood disorders. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-10-13 Francesco Weiss, Giulio Emilio Brancati, Camilla Elefante, Alessandra Petrucci, Teresa Gemmellaro, Lorenzo Lattanzi, Giulio Perugi
The association between mood disorders, especially bipolar disorder (BD), and metabolic disorders, is long known. However, to which extent metabolic disorders affect the course of mood disorders in late life is still open to inquiring. To assess the impact of type 2 diabetes mellitus (T2DM) on late-life mood disorders a retrospective chart review was performed. Elderly depressive patients (≥ 65 years)
-
Neuropsychiatric symptoms in a patient under cystic fibrosis transmembrane conductance regulator modulators treatment: a case report. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-09-27 Helena Andreu, Luis Olivier, Anna Giménez-Palomo, Carmen Roson-Fernandez, Laura Bueno, Óscar de Juan, Inés Bartolomé, Lidia Ilzarbe, Laia Tardón-Senabre, Tabatha Fernández-Plaza, Néstor Arbelo, Marc Valentí, Joaquín Gil-Badenes, Elisabet Macau, Gabriel Pujol-Fontrodona, Lluc Colomer, Eduard Vieta, Isabella Pacchiarotti
In recent times, some research has focused on the study of potential treatments for cystic fibrosis (CF), such as cystic fibrosis transmembrane conductance regulator (CFTR) modulators. These treatments have been reported to produce neuropsychiatric symptoms in a few patients, even though there is still no clear correlation nor underlying mechanism proposed. We present the case of a 23-year-old woman
-
Catatonic postpartum paternal depression as a first debut of a bipolar disorder: a case report. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-09-20 Oscar de Juan, Albert Mas, Anna Giménez-Palomo, Joaquín Gil-Badenes, Lídia Ilzarbe, Lluc Colomer, Helena Andreu, Laura Bueno, Luis Olivier, Beatriz Estévez, Tábatha Fernández-Plaza, Laia Tardón-Senabre, Néstor Arbelo, Marc Valentí, Susana Gomes da Costa, Gabriel Pujol-Fontrodona, Eduard Vieta, Isabella Pacchiarotti
Paternal postpartum depression (PD) is considered an affective disorder that affects fathers during the months following childbirth. Interestingly, it has been observed that during these months the chances of a male parent suffering from depression are double that for a non-parent male counterpart. We present the case of a 34-year-old man with no relevant medical history in who, overlapping her daughter's
-
Manic episode in a patient with pancreatic adenocarcinoma: a case report. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-09-20 Juan I Mena, Helena Andreu, Anna Giménez-Palomo, Laura Bueno, Eduard Cesari, Óscar De Juan, Iñaki Ochandiano, Luis Olivier, Sergi Salmeron, Eduard Vieta, Isabella Pacchiarotti
Psychiatric comorbidity is common in cancer patients, emphasizing the need for comprehensive care. While depressive symptoms in pancreatic cancer have been studied, there is limited attention given to manic symptoms. This case report aims to contribute to the knowledge of pancreatic cancer psychiatric comorbidities by describing a case of a patient with stage IV pancreatic cancer who presented a sudden
-
A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-09-20 Medhat M Bassiony, Nelly R Abdelfattah, Amany Elshabrawy, Mary M Adly
Tramadol and venlafaxine share similar pharmacological characteristics that may allow for overlapping therapeutic indications for them. The objective of this study was to compare the efficacy of venlafaxine and naltrexone in the treatment of tramadol abuse. This comparative trial included 95 patients with tramadol abuse who were detoxified for 2 weeks. Twenty-eight participants underwent the maintenance
-
Valbenazine for tardive dyskinesia: a systematic review and network meta-analysis. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-09-12 Taro Kishi, Kenji Sakuma, Nakao Iwata
To date, the role of valbenazine (VAL) in a dose-dependent increase in efficacy for tardive dyskinesia (TD) and in the worsening of acceptability and tolerability in a dose-dependent manner remains to be elucidated. Thus, in this systematic review and frequentist network meta-analysis, we compared 16 outcomes of VAL80 mg/d (VAL80) with VAL40 mg/d (VAL40) related to the efficacy, acceptability, tolerability
-
Differential effectiveness between Ketamine and Esketamine: the predictive role of dissociative features. A treatment-resistant depression case. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-08-07 Nicola Ragone, Barbara Barbini, Carolina Passani, Federico Seghi, Cristina Colombo
More than 10 years ago, the discovery of the antidepressant effects of Ketamine opened the opportunity to develop a novel class of antidepressants. Ketamine induces dissociative symptoms as a major side effect. This rapid-acting antidepressant is available as an endovenous racemic compound and as an intranasal S-enantiomer: Esketamine; which is four-fold more potent for the NMDA receptor. Here we present
-
Capillary blood sampling for the determination of clozapine concentrations: analytical validation and patient experience. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-08-07 Bianca D Breken, Koen P Grootens, Annemieke M Vermeulen Windsant-van den Tweel, Walter A Hermens, Hieronymus J Derijks
Patients may be reluctant to start clozapine (CLZ) because of the frequent blood sampling needed for white blood cell monitoring, but also therapeutic drug monitoring of CLZ. Finger prick, instead of venepuncture, might lower the threshold to CLZ use. The aim of this study was to determine whether CLZ concentrations are the same in capillary and venous blood samples. Capillary blood was drawn by finger
-
Possible genetic biomarker associated with antipsychotic-induced amenorrhea in female patients with schizophrenia. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-08-07 Jung-Joon Moon, Ho-Sook Kim, Joo-Cheol Shim, Jung-Mee Ahn, Do-Un Jung, Dong-Jin Kim, Hye-Eun Jeong, Eun-Young Kim, Dong-Wook Jeon, Sung-Jin Kim, Jae-Gook Shin
This study explored the association of pharmacogenomics with antipsychotic-induced amenorrhea in female patients with schizophrenia. A total of 89 female schizophrenia patients aged 18-40 receiving consistent antipsychotics at a consistent dose for more than 3 months were enrolled in this study. Amenorrhea was defined as the absence of menstrual period for 3 months or three periods in a row. Serum
-
The effects of psychological flexibility and resilience on psychopharmacological treatment response in patients with obsessive-compulsive disorder. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-08-07 Nisa Deveci, Mustafa Uğurlu, Görkem Karakaş Uğurlu, Esra Kabadayi Şahin, Ezgi Çisil Erdoğan, Ali Çayköylü
Obsessive-compulsive disorder (OCD) is a challenging psychiatric condition to treat. Previous research has explored various aspects of treatment response, but limited attention has been given to the significance of psychological flexibility and resilience. This study aimed to investigate the correlation between psychological flexibility, resilience, and different dimensions of OCD, as well as their
-
l-carnitine adjunct to risperidone for treatment of autism spectrum disorder-associated behaviors: a randomized, double-blind clinical trial. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-08-07 Mehry Nasiri, Zohal Parmoon, Yalda Farahmand, Ali Moradi, Kimia Farahmand, Kamyar Moradi, Fatemeh A Basti, Mohammad-Reza Mohammadi, Shahin Akhondzadeh
Present study was designed to evaluate the efficacy and safety of l-carnitine as an adjuvant agent to risperidone in the treatment of autism spectrum disorder (ASD)-associated behaviors. In this study, 68 children with confirmed ASD were randomly allocated to receive either l-carnitine (150 mg/day) or matched placebo in addition to risperidone. We utilized the Aberrant Behavior Checklist-Community
-
Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-08-07 Rakesh Jain, Roger S McIntyre, Andrew J Cutler, Willie R Earley, Huy-Binh Nguyen, Julie L Adams, Lakshmi N Yatham
Post hoc analyses evaluated cariprazine, a dopamine D3-preferring D3/D2 receptor partial agonist, in patients with bipolar I depression and high baseline anxiety. Data were pooled from two phase 3, randomized, double-blind, placebo-controlled studies in adults with bipolar I disorder and a major depressive episode (NCT02670538, NCT02670551). Cariprazine 1.5 and 3 mg/d were evaluated in patient subgroups
-
Relationship between clinical efficacy and plasma concentration-dose ratio of risperidone in patients with schizophrenia. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-07-19 Qiuying Chen, Jie Min, Haibo Yin, Wenying Xia, Yimin Shen, Ming Shu
This study aimed to retrospectively explore the relationship between clinical efficacy and plasma concentration-dose ratio of risperidone (RIS) in 252 patients with schizophrenia taking RIS orally. After the same dose of RIS treatment, the plasma concentration of RIS/9-hydroxyrisperidone (9-OH-RIS), the total plasma concentration of RIS, and the ratio of the steady-state plasma concentration to the
-
Assessing the relationship between antipsychotic drug use and prolidase enzyme activity and oxidative stress in schizophrenia patients: a case-control study. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-07-19 Ece Yazla, Ihsan Cetin, Huseyin Kayadibi
The relationship between proline, its association with oxidative stress, and its connection to schizophrenia is a subject that has not been sufficiently investigated.
-
Long-term remission following esketamine nasal spray sessions in a patient with severe and highly treatment-resistant depression: a single-case report. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-07-11 Lucas Arrighi, Eloïse Maakaron, Théo Korchia, Christophe Lançon, Raphaëlle Richieri
About 30% of patients with major depressive disorder have treatment-resistant depression (TRD). Recently, intranasal esketamine was approved as a treatment option after the failure of two antidepressant trials. We report a patient with multiresistant depression that was successfully and safely treated with esketamine nasal spray. This 31-year-old inpatient with severe, chronic, and multi-TRD received
-
Does the comorbidity of borderline personality disorder affect the response to treatment in bipolar patients? Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-07-04 Cecilia Maria Esposito, Jennifer L Barkin, Alessandro Ceresa, Massimiliano Buoli
Bipolar disorder (BD) is a highly prevalent condition whose response to pharmacological treatment is associated with a number of factors including psychiatric comorbidity. Borderline personality disorder (BPD) shares clinical symptoms and biological vulnerability with BD and the two conditions are frequently comorbid, thus representing a clinical challenge. The purpose of the present review is to summarize
-
Clinical specificity profile for novel rapid acting antidepressant drugs. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-06-30 Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, Alessandro Serretti, Chiara Fabbri
Mood disorders are recurrent/chronic diseases with variable clinical remission rates. Available antidepressants are not effective in all patients and often show a relevant response latency, with a range of adverse events, including weight gain and sexual dysfunction. Novel rapid agents were developed with the aim of overcoming at least in part these issues. Novel drugs target glutamate, gamma-aminobutyric
-
'The Gordian knot of the immune-redox systems' interactions in psychosis'. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-06-12 Evangelos Karanikas
During the last decades the attempt to enlighten the pathobiological substrate of psychosis, from merely focusing on neurotransmitters, has expanded into new areas like the immune and redox systems. Indeed, the inflammatory hypothesis concerning psychosis etiopathology has exponentially grown with findings reflecting dysfunction/aberration of the immune/redox systems' effector components namely cytokines
-
Sex-specific clinical characteristics and treatment responses in delirium management: findings from a prospective cohort study in elderly patients. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-06-12 Florian F Hildenbrand, Soenke Boettger, Tobias Spiller, Maria Schubert, Jutta Ernst, Roland von Känel, Carl M Zipser
Delirium incidence and phenotype differ between sexes. Sex differences in the selection of treatment strategies remain elusive. We evaluated sex-specific responses to non- and pharmacological management. In this observational prospective cohort study conducted at the University Hospital Zurich, Switzerland, 602 patients managed for delirium were analyzed. Remission and benefit ratios of treatments
-
Temperament and character dimensions explain self-reported resilience deficits in patients with affective disorders. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-06-12 Evdoxia Tsigkaropoulou, Ioannis Michopoulos, Evgenia Porichi, Konstantinos Dafnas, Alessandro Serretti, Panagiotis Ferentinos
This is the first study exploring how temperament and character personality dimensions impact self-reported resilience in major depressive disorder (MDD) and bipolar disorder (BD). We included 130 euthymic patients with affective disorders (AFD; 66 MDD and 64 BD) and 134 healthy controls (HC). Connor and Davidson resilience scale and Temperament and Character Inventory (TCI-140) were administered.
-
Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-06-12 Chelsea Boydstun, Sean Lynch, Patrick DiGenova
Schizophrenia is a chronic mental health condition treated with antipsychotics. A significant number of patients fail to respond to standard treatment and develop treatment-resistant schizophrenia (TRS). The only current treatment for TRS is clozapine, which has significant side effects and may only be effective in 40% of cases. We describe two cases of patients with TRS who have failed multiple antipsychotic
-
Antidepressant emergent mood switch in major depressive disorder: onset, clinical correlates and impact on suicidality. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-06-12 Paolo Olgiati, Alessandro Serretti
Antidepressant (AD)- emergent mood switch (AEMS) is a common complication of bipolar depression. This study aimed to investigate the prevalence and clinical correlates of subthreshold AEMS (i.e. not fulfilling DSM criteria for hypomanic episodes) in major depressive disorder (MDD) and, prognostically, its impact on AD treatment outcome and suicidality. The study involved 425 outpatients with MDD followed
-
Navigating the pharmacologic complexities of QTc prolongation: assessing the cumulative burden in individuals with serious mental illness. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-15 Tammie Lee Demler, Carolyn O'Donnell
The scientific progress made in the pharmacologic management of serious mental illness (SMI) has been significant. However, the benefits of medication management must continually be weighed against the risks of adverse effects of the agents prescribed. While many medications pose increased danger of QTc prolongation, which may result in malignant arrhythmia and sudden cardiac death, the combination
-
DRESS syndrome: quetiapine associated case report and literature review. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-08 Hannah L Mallaro, Lisa J Rosenthal
Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a rare systemic adverse drug reaction with a high mortality rate. Cases of DRESS syndrome have been reported with almost all classes of psychiatric medications, but data remains limited. We describe the case of a 33-year-old woman who presented with acute respiratory distress syndrome secondary to severe pulmonary blastomycosis.
-
Ketamine for depression: a potential role in requests for Medical Aid in Dying? Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-04-18 Nicolas Garel, Michka Nazon, Kamran Naghi, Elena Willis, Karl Looper, Soham Rej, Kyle T Greenway
Medical Aid in Dying (MAiD) is the act of a healthcare provider ending a patient's life, at their request, due to unbearable suffering from a grievous and incurable disease. Access to MAiD has expanded in the last decade and, more recently, it has been made available for psychiatric illnesses in a few countries. Recent studies have found that such psychiatric requests are rapidly increasing and primarily
-
Neuroscience-based nomenclature as a teaching tool, introduction and pilot study. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-04-12 Sasson Zemach, Daniel Minkin Levy, Joseph Zohar
Neuroscience-based nomenclature (NbN) is a pharmacologically-driven nomenclature aiming to replace the current disease-based nomenclature of psychotropics, focusing on pharmacology and mode-of-action to encourage scientifically-minded prescribing. NbN might also be used as a teaching tool as it presents the depth and richness of the neuroscience of psychotropics. This study examines the effect of using
-
Does celecoxib with sodium valproate have an augmentation effect on acute mania in bipolar disorder? A double-blind controlled clinical trial in Iran. Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-04-12 Farhad Faridhosseini, Ali Talaei, Najmeh Shahini, Zanireh Salimi, Mahboubeh Eslamzadeh, Samira Ahrari, Meysam Pourgholami, Majid Khadem-Rezaiyan
Inflammatory processes in the brain play a role in acute mania etiopathogenesis. There is little evidence indicating the efficacy of celecoxib adjuvant therapy in treatmenting of manic episodes of bipolar disorder. Therefore, this clinical trial aimed to assess the celecoxib effect on treating acute mania. In a double-blind, placebo-controlled trial, 58 patients meeting the criteria for acute mania
-
Investigating the psychological effects of home quarantine during the early peaks of the COVID-19 pandemic: a survey from Iran Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-01 Mahsa Nahidi, Mojtaba Ghalandarzadeh, Farideh Sinichi, Narjes Sahebzadeh, Saeid Eslami, Hamidreza Reihani, Maryam Emadzadeh, Mohammad Reza Fayyazi Bordbar
We assessed psychological symptoms among individuals who were quarantined during early coronavirus disease 2019 (COVID-19) peaks. This cross-sectional study was performed during April–October 2020 in Iran. We surveyed 100 individuals with COVID-19 patients in their families and 100 others with health conditions associated with a higher risk of developing critical forms of COVID-19 infection, who have
-
Can bupropion treat COVID-19–induced brain fog? A case series Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-01 Samuel Reinfeld
COVID-19–induced neurocognitive complications that include brain fog have affected a large portion of individuals who survived COVID-19. These symptoms can include inattention, mental fatigue, forgetfulness, amotivation, and distractibility. This can cause significant anxiety and depression, which may worsen disease progression. To date, there are no known specific treatments that target COVID-19-related
-
Unhealthy lifestyle impacts on biological systems involved in stress response: hypothalamic–pituitary–adrenal axis, inflammation and autonomous nervous system Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-01 Laura Mandelli, Yuri Milaneschi, Sarah Hiles, Alessandro Serretti, Brenda W. Penninx
An unhealthy lifestyle has a critical role in the pathogenesis and course of several chronic disorders. It has been hypothesized that lifestyle may also impact biological systems involved in stress response. A global index of unhealthy lifestyle was calculated based on the cumulative presence of five self-reported lifestyle habits (smoking, excessive alcohol use, drug use, low physical activity and
-
Associations of adolescent psychosocial factors to later benzodiazepine use: a population-based follow-up study of adolescent psychiatric inpatients in Northern Finland Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-01 Emmi Kujala, Helinä Hakko, Pirkko Riipinen, Kaisa Riala
We investigated factors associated with benzodiazepine (BZD) use during late adolescence and early adulthood. The study population consisted of 508 adolescents admitted to psychiatric inpatient care between April 2001 and March 2006. Information on adolescents’ family- and school-related factors, suicidality and psychiatric disorders were obtained by semistructured interviews. Data on BZD prescriptions
-
Suicidality in a psychiatric inpatient unit: a 2-year retrospective study in Umbria, central Italy Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-01 Eleonora Valentini, Sara Bianchi, Giulia Menculini, Antonia Simona Cusenza, Eleonora Balena, Pierfrancesco Maria Balducci, Kety Amantini, Patrizia Moretti, Alfonso Tortorella
Suicide ranks among the 10 leading causes of death worldwide; in Italy, almost 4000 persons per year die by suicide. Studies focusing on suicidality in Italian inpatient samples before the COVID-19 pandemic are scant. We, thus, aimed to define sociodemographic and clinical variables associated with suicidal ideation (SI) and deliberate self-harm (DSH) in a sample of inpatients admitted to a Psychiatric
-
Cardiovascular risk factors and metabolic syndrome in patients treated with long-acting injectables antipsychotics: a retrospective study Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-01 Vera De Carlo, Benedetta Grancini, Niccolò Cassina, Lorenzo Casati, Eleonora Piccoli, Matteo Vismara, Dario Gobbo, Raffaella Zanaschi, Susanna Lupo, Silvia Olivieri, Bernardo Dell’Osso
The present cross-sectional, retrospective study aimed to assess the prevalence of cardiovascular disease (CVD) risk factors and metabolic syndrome in a sample of psychiatric patients treated with long-acting injectable antipsychotics (LAIs). The clinical charts of 120 patients, mainly diagnosed with schizophrenia (30.0%), schizoaffective disorder (15.0%), and bipolar disorder (13.3%) on LAIs therapy
-
Characteristics and outcomes of cases with methylphenidate abuse, dependence or withdrawal: an analysis of spontaneous reports in EudraVigilance Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-01 Lara T. Hartmayer, Falk Hoffmann, Christian J. Bachmann, Kathrin Jobski
Methylphenidate (MPH) is a central nervous stimulant, which is mainly used in attention deficit hyperactivity disorder (ADHD) and narcolepsy. In recent years, rising MPH prescription volumes have drawn attention to possible misuse. We analyzed data on suspected MPH abuse, dependence or withdrawal reported to the EudraVigilance database (1996–2019), comparing case characteristics (e.g. age, indications
-
Sleep disturbance in schizophrenia spectrum disorders: more than just a symptom? Int. Clinical Psychopharmacol. (IF 2.6) Pub Date : 2023-05-01 Fabio Ferrarelli
Sleep disturbance is commonly reported in patients with schizophrenia spectrum disorder (SSD) in the clinical setting. Sleep features can be assessed subjectively, with self-report sleep questionnaires, and objectively with actigraphy and electroencephalogram recordings. Traditionally, electroencephalogram studies have focused on sleep architecture. More recently, numerous studies have investigated